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ABSTRACT 
The mucus layer covering the colonic epithelium creates a crucial first line of 
defense against the gut residing bacteria. Several lines of evidence suggest that 
a functional mucus layer is essential for health. For example, it is. suggested 
that ulcerative colitis is correlated with mucus layer defects. The barrier 
properties of colonic mucus are partly achieved by creating a dense gel with 
the MUC2 gel-forming mucin as scaffold. Available MUC2 biochemical and 
histological data suggest that the mucus is highly structured and organized. 
Mucus homeostasis is dependent on production, secretion and processing of 
mucus components. Thus, factors such as goblet cell differentiation, secretory 
capacity of different cells, and the presence of mucus degrading proteases can 
affect mucus properties. However, a detailed understanding of mucus structure 
and processing in vivo is lacking. 
We have now further developed an existing ex vivo system to study the mucus 
structure at the microscopic level, as well as investigate the involvement of 
subpopulations of goblet cells in mucus secretion. This ex vivo method was 
also used for studies of mucus proteolytic processing by CLCA1, an abundant 
protease within the mucus.  The results suggest that the colonic mucus gel is 
heterogeneous due to the presence of different goblet cell populations that 
secrete mucus with different properties. Furthermore, proteolytic processing of 
MUC2 by CLCA1 is involved in baseline mucus dynamics.  
Increased understanding of mucus structure and processing is important for 
future development of pharmacological interventions to improve barrier 
function in ulcerative colitis and prevent mucus stagnation in diseases such as 
asthma, chronic obstructive lung disease and cystic fibrosis. 
 
Keywords; lectin, CLCA1, SPDEF, MUC2, colitis, mucus structure, mucus 
dynamics, mucus homeostasis  
  
 
 
  
SAMMANFATTNING PÅ SVENSKA 
Goblet celler är specialiserade celler i tjocktarmens slemhinna som producerar 
och utsöndrar proteiner som bygger upp ett gellager, även kallat mukus, 
närmast slemhinnans ytceller (epitelet). Mukuslagret bildar en skyddande 
barriär mellan epitelet och de triljoner bakererier som lever i tjocktarmen. 
Defekter i barriären är kopplat till olika sjukdomar, till exempel 
inflammatorisk tarmsjukdom. Att bättre förstå vilka faktorer som har betydelse 
för mukusets egenskaper kan bidra till bättre kunskap om dessa sjukdomar och 
i förlängningen leda till nya behandlingsmetoder. 
MUC2 är det protein som bildar mukusets stomme, och det är visat att MUC2- 
molekylerna är välorganiserade i mukuset genom specifika interaktioner 
mellan olika MUC2-molekyler. Däremot vet man mindre om funktionen av 
andra proteiner som finns i mukuset, t.ex. CLCA1.  
I denna avhandling har vi använt en metod som låter oss studera hur mukuset 
ser ut och beter sig i levande vävnad genom att dissekera ut slemhinnan med 
mukus och studera den under mikroskop. Eftersom mukuset är transparant har 
man tidigare förlitat sig på små partiklar som man lägger ovanpå mukuset för 
att dra slutsatser om mukuskvalitén. Här har vi dock kunnat visa att man genom 
att använda fluoroscerande molekyler som binder till mukuset kan titta på 
själva mukusstrukturen. På så sätt har vi kunnat visa att tjocktarmsmukus 
består av två sammankopplade strukturer; plymer av väldigt tätt mukus som 
täcker och skyddar känsliga öppningar (krypor) i epitelet, och 
”mellankryptsmukus” som länkar samman plymerna. Vi har även kunnat visa 
att de två olika typerna av mukus utsöndras av olika, tidigare obeskrivna, 
subpopulationer av goblet celler. Genetiskt modifierade möss som saknar 
mellankrypsmukus utvecklar inflammation i tjocktarmen och det verkar därför 
som att mellankryptsmukus är viktigt för mukuslagrets skyddande funktion. 
Vidare har vi kunnat visa att CLCA1 i mukus fungerar som ett enzym som kan 
klyva MUC2 och därmed ändra strukturen på mukuset. Denna process pågår 
till viss del konstant, men våra resultat tyder även på att det är en noggrant 
reglerad process. Upptäckten att CLCA1 kan påverka mukuset kan ha stor 
betydelse för förståelsen av astma och kronisk obstruktiv lungsjukdom (KOL), 
eftersom uttrycket av CLCA1 korrelerar med dessa.  
Sammntaget har vi fört fårståelsen om hur mukuset är uppbyggt och hur det 
processas framåt, vilket vi hoppas ska stimulera fortsatt forskning på hur 
mukuset ändras vid sjukdom. Framtida resultat kan därför komma att leda till 
bättre behandling av sjukdomar som involverar förändringar i mukuset. 
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1 INTRODUCTION 
 
1.1 Intestinal mucus 
The number of cells in the human body is equaled by the bacterial cells residing 
in our gut. These bacteria are beneficial to the host, e.g. by providing essential 
nutrients such as vitamins, and by degrading complex fibers into host 
accessible derivatives 1. However, pathogenic, as well as commensal, bacteria 
cause harm if they are in direct contact with the epithelium 2,3. The intestinal 
tract is thus covered by a gel-like mucus layer that serves as protection of the 
underlying epithelium by providing a barrier between the host tissue and the 
microbiota as well as lubricating the tissue. 
1.1.1 Mucus properties along the gastrointestinal tract 
The mucus layer is continuous throughout the gastrointestinal (GI) tract but 
has varying properties dependent on location (Figure 1A). For example 
MUC5AC is the main gel-forming mucin in the stomach, whereas MUC2 
dominates in the small and the large intestine 4. Furthermore, mucus in the 
small intestine is non-attached to the epithelium and loosely structured. This 
allows for efficient nutrient uptake while providing a diffusion barrier for anti-
microbial peptides which protect the epithelium 5,6. In contrast, the distal colon 
has a two-layered (“inner” and “outer”) mucus structure 3,5–8. The dense 
structure of the attached inner mucus layer has been investigated by size 
exclusion of µm-sized beads and has been found to exclude beads with the size 
of bacteria 7. This is reflected in the ability of the inner mucus layer to separate 
the bacteria in the fecal content from the epithelium, thus forming a physical 
barrier between the microbiota and the epithelium in the gut (Figure 1B) 3. 
The inner mucus layer is continuously converted to an outer mucus layer. The 
outer mucus layer is not attached, and has a looser structure due to digestion 
and expansion mediated by endogenous proteases (discussed further in 1.1.3.3) 
3. In contrast to the mostly sterile inner mucus layer, the outer mucus layer 
creates a habitat for the microbiota by providing a nutrient source and sites for 
adhesion. 
Colonic mucus structure and processing 
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Figure 1: A) Schematic representation of mucus along the gastrointestinal tract. Stomach 
and colonic epithelia are covered by a two-layered mucus with an attached inner layer (dark 
color), and a non-attached outer (light color) mucus with MUC5AC (yellow/orange) and 
MUC2 (green) as main mucin component in the stomach and colon respectively. Villi in the 
small intestine are covered by a loose, non-adherent mucus with MUC2 as main mucin. B) 
Schematic representation of the mucus layer organization in colon, with the stratified inner 
mucus (IM) layer and outer mucus (OM) layer. Microbiota is restricted to the outer mucus 
layer. Epith. = epithelium, GC = goblet cell, EC = enterocytes 
 
1.1.2 Mucus composition 
Proteome analysis of intestinal mucus has identified a core set of proteins that 
are present in the intestinal mucus along the GI tract, both in human and mouse 
3,4 (van der Post et al., submission). The main structural component, the MUC2 
mucin, is accompanied by calcium-activated chloride channel regulator 1 
(CLCA1) (further introduced in 1.3), Fc-gamma protein binding protein 
(Fcgbp), zymogen granule protein 16 (Zg16), and kallikrein 1 (Klk1). Zg16 
was recently found to bind and aggregate gram-positive bacteria, thus keeping 
them away from the epithelium 9, but the function of most other proteins found 
in mucus is still largely unknown. 
Mucus also contains material from shed cells. Thus, proteins and DNA 
normally found intracellularly are found in mucus 4,10. These compounds might 
play an active role in the mucus after secretion, and alter the mucus properties 
10,11. However, very little is known about the activity and functional importance 
of these compounds in the secreted mucus. 
Elisabeth Nyström 
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1. 1.2.1 Biochemical properties of MUC2  
As mentioned, MUC2 is the main structural component of intestinal mucus and 
provides a scaffolding backbone. MUC2 is a large, > 5000 amino acids, gel-
forming mucin. The domain structure in MUC2 (as well as other gel-forming 
mucins) resembles that of the von Willebrand factor (VWF) 12,13 and are 
arranged in the following order; von Willebrand D1 assembly (D1), D2, D′D3, 
a first cysteine domain (CysD), small proline, threonine and serine rich (PTS) 
domain, second CysD, large PTS domain, C-terminal D4 followed by von 
Willebrand C assemblies, and a cysteine-knot domain (CK) (Paper III, Figure 
3D). The von Willebrand D assemblies can be further subdivided into von 
Willebrand D-domain (vWD), C8-module, trypsin inhibitor-like (TIL)-
domain, and a fibronectin type 1-like (E)-domain, except the D´ which only 
contains a TIL- and E-domain 14. 
The PTS domains, also called mucin domains, are hallmark features of mucins. 
These domains are heavily O-glycosylated in the Golgi which gives the protein 
a stretched, brush-like arrangement. After secretion, the glycans become 
hydrated which gives the mucus its gel-like properties and provides lubrication 
15. The attached glycans protect the MUC2 backbone from proteolytic 
degradation by endogenous or bacterial enzymes 16–18. However, they also 
serve as adhesion sites for several bacteria and can thus provide a way for the 
host to select commensal members from the microbial community 19,20, but can 
also be exploited by pathogens. Moreover, the MUC2 glycoprotein can serve 
as a nutrient source for bacteria when their preferred metabolic substrates are 
lacking, which grants them a niche benefit and might lead to dysbiosis 21,22. 
The O-glycan pattern is specific for the different GI regions, as well as the host 
species. For example, human small intestinal mucus is highly fucosylated, 
whereas small intestinal mucus is only sparsely fucosylated in mice 23,24. 
Furthermore, core-3 glycan structures are abundant in human colonic mucus 
whereas mouse colonic mucus mainly contains core-1 and core-2 structures. 
Core-4 structures can be found in colonic mucus from both species. However, 
colonic mucus O-glycans from both humans and mice are commonly 
terminated by fucose, sialic acid and sulphate. 
The attachment of O-glycans increases the molecular mass of MUC2 by 
approximately 500%, and the resulting MUC2 monomer thus has a molecular 
mass of around 2.5 MDa 17. Additionally, MUC2 undergoes C-terminal 
Colonic mucus structure and processing 
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dimerization in the endoplasmic reticulum, and N-terminal trimerization of the 
D3-assembly in the secretory pathway, generating huge MUC2 oligomers 25–27 
(Figure 2). Decreased pH and increased calcium concentration in the secretory 
pathway aids dense packing of the MUC2 oligomers in secretory vesicles.  The 
D1-D2 assemblies are suggested to facilitate packing by providing non-
covalent interaction between the D3-trimers, similar to the function of D1-D2 
to stabilize the organized intracellular structure of VWF in Weibel-Palade 
bodies 28,29.  
MUC2 oligomers unfold and expand into huge netlike sheets upon secretion. 
This process is suggested to be mediated by bicarbonate by precipitating 
calcium and increasing the pH 28,30,31 (Figure 2). It’s further thought that these 
sheets are continuously pushed towards the intestinal lumen by newly secreted 
MUC2 sheets, which thus stacks the nets on top of each other 32. 
Immunohistochemical (IHC) examination of MUC2 in colonic cross sections 
from both mouse and human shows a stratified appearance in the inner mucus 
layer which has supported this notion 3,8. Formation of non-reducible bonds 
between separate MUC2 molecules, mediated by transglutaminases, is 
suggested to keep the different layers of MUC2 sheets associated 11. The 
MUC2 three-dimensional mesh thus acts as a sieve which can exclude bacteria. 
 
Figure 2: Schematic picture of MUC2 oligomerization by C-terminal dimerization and N-
terminal trimerization, intracellular packing, extracellular unpacking and stacking into MUC2 
sheets in the IM. 
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1.1.3 Mucus dynamics 
Mucus homeostasis is maintained by a dynamic balance between production, 
secretion and proteolysis of mucus components (Figure 3). Mucus homeostasis 
is also dependent on the ionic milieu it is secreted into, as evident in the small 
intestine of mice that lack a functional CFTR ion channel where mucus remains 
attached to the epithelium due to lack of bicarbonate secretion 3,13,28,31.  
1.1.3.1 MUC2 production 
Colonic MUC2 is constitutively expressed in order to constantly renew the 
mucus layer 32–34. Production of MUC2 can be enhanced by several stimuli 
including bacterial components, TH1-, and TH2- mediated cytokines, acute 
phase responses, and viral infection 35–45. Considering the high rate of MUC2 
biosynthesis, especially in surface epithelial goblet cells, altered MUC2 
production is likely to affect mucus dynamics within a few hours 32,34. 
1.1.3.2 Mucus secretion  
The densely packed MUC2 oligomers are stored in secretory vesicles in the 
goblet cell theca. The content of these vesicles is released either by regulated 
vesicle secretion, sometimes referred to as baseline secretion, or by stimulated 
compound exocytosis 46. Baseline secretion has mainly been studied in 
airways, and is shown to be dependent on SNARE proteins which are typically 
involved in vesicle exocytosis 47. Several VAMP and SNARE-proteins are 
found in the mucin granules in cultured cells of colonic origin suggesting that 
similar functions are important also in the intestine 48. Additionally, mice 
lacking Munc13-2 or VAMP8, which are involved in baseline exocytosis, have 
goblet cell mucus accumulation in the intestine and impaired secretion 49,50. 
In compound exocytosis, storage vesicles rapidly fuse with each other and the 
cell membrane, which enhances the secretion as the whole theca contents is 
secreted from the cell 51. It is triggered by different stimuli via intracellular 
calcium signaling. In goblet cells this has been observed after stimulation with 
the cholinergic agonist carbachol (CCh), which induces almost complete 
emptying of goblet cells in the intestinal crypts 7,51–53. The mast cell product 
histamine, the neuropeptide VIP, and the immune regulator PGE2 have similar 
effects, however the goblet cell response varies along the GI tract and also 
between species as reviewed in Birchenough et al., 2015 46. Furthermore, it 
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was recently described how goblet cells at the crypt opening can endocytose 
bacterial molecules and, if at high enough concentration, mount a secretory 
response involving compound exocytosis to clear the crypt opening from 
intruding bacteria 54.  
Pulsed in vivo labelling of glycoprotein in mouse colonic tissue has shown that 
goblet cells throughout the crypt continuously renew their stored material over 
the time course of a couple of hours to a couple of days and thus continuously 
secrete and produce MUC2 32. However, the rate of production and secretion 
differs along the crypt axis; Goblet cells at the luminal surface of the 
epithelium had a markedly higher turnover of their mucin content compared to 
goblet cells residing in the crypts. In the luminal cells newly produced material 
was secreted as soon as 3 hours post labelling, and most of the pulse-labelled 
material was secreted within 7 hours. In contrast, crypt residing cells had both 
slower production and renewal of their content, and pulse-labelled material 
was still observed 24 hours post injection. Similar differences in MUC2 
turnover were also found in small intestine 34. However, determinants of mucus 
turnover rate in different cells are still unknown.  
1.1.3.3 Mucus expansion by unfolding and proteolytic processing of MUC2 
MUC2 molecules are thought to expand >1000 times upon secretion as the 
calcium concentration drops and pH increases 28.  The environmental changes 
induce conformational alterations in MUC2 D1-D2 which breaks the 
interaction between D1-D2 and D’-D3, allowing the unfolding. The removal 
of calcium also allows the electrorepulsive forces between glycosylated PTS-
domains to drive unfolding. Despite the fact that bicarbonate is secreted from 
the epithelium, a pH gradient has been noted in rat colonic mucus where the 
pH increased towards the luminal center 55. It is thus possible that the unfolding 
of the densely packed MUC2 molecules is a gradual process. However, the 
unfolding/expansion of MUC2 has not been investigated in great detail, 
although the homogenous stratified appearance of the inner mucus layer in IHC 
indicates that the unfolding is rapid and results in an inner mucus layer that has 
a homogenous MUC2 organization 3. 
The conversion from the attached, dense, inner mucus layer to the unattached, 
looser, outer mucus layer is at least partly dependent of proteolytic activity in 
the mucus. This has been inferred from the finding that inhibition of cysteine-
and serine proteases decreases the formation of an outer mucus layer both in 
Elisabeth Nyström 
1 INTRODUCTION  7 
mouse and in rat samples, seen as reduced mucus growth ex vivo 3. As germ-
free (GF) mice seem to have a similar mucus organization to conventionally 
raised mice in terms of an inner and outer mucus layer, the responsible 
proteases are endogenous to the host. The outer mucus layer is penetrable of 
bacteria sized beads indicating that the outer mucus layer has larger pore size 
than the inner mucus layer 7. The proteolytic cleavage thus alters the MUC2 
network structure, but without completely breaking it, and is suggested to 
occur in the terminal domains. It has further been shown that trypsin treatment 
of the guanidinium chloride insoluble fraction of Muc2 expands but does not 
dissolve the structure, supporting the notion that proteolysis of MUC2 can lead 
to volume expansion without complete disruption 3. 
We most often consider mucus homeostasis and dynamics in terms of MUC2; 
however, the mucus and epithelium also contains an array of other components 
that can possibly greatly influence all the processes described above. These 
include Agr2 and Ern2, which are important for the production and secretion 
of Muc2, ion channels for correct ionic milieu in the lumen, and other 
suggested structural components such as Fcgbp. However, the available 
functional information on other mucus components are thus far limited 30,31,56–
58.  
   
 
Figure 3: Schematic drawing of the different levels of mucus dynamic control. 
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1.1.4 Physiological relevance and clinical importance 
Although the lubricating properties of GI mucus has long been appreciated, its 
true involvement in health and symbiosis with our GI-residing microbiota has 
only recently been explored. Mucus-microbiota symbiosis, or dysbiosis, has 
received a great deal of interest in relation to the growing problem with 
inflammatory bowel disease (IBD) e.g. ulcerative colitis (UC), and has also 
been suggested to be involved in metabolic syndrome 22,59–62.  
1. 1.4.1 Colitis 
Inflammatory bowel disease can be broadly divided into Crohn’s disease and 
UC. There are several reports correlating mucus defects with UC or animal 
colitis models 30,63–68. Furthermore, UC patients have been shown to have 
abnormal contact between bacteria and the epithelium 64,69, and it is thus 
reasonable to speculate that the aforementioned mucus defects allow bacterial 
penetration into the mucus layer. This might drive increased or abnormal 
immune response, and “wear out“ mucus production if the infection is 
prolonged, and thereby cause a negative feedback loop 70. 
The colonic mucus layer is thinner in patients with active UC compared to 
healthy controls 64,71. More importantly, colonic mucus from a majority of the 
patients with active UC was found to be penetrable to bacteria-sized beads ex 
vivo, in contrast to healthy controls which had impenetrable mucus 64. 
Interestingly, most patients in remission had impenetrable mucus, but a few 
were similar to the active UC group. This indicated that the mucus dysfunction 
recovers during remission. Whether or not mucus dysfunction preceded colitis 
in humans could not be determined, but in animal models of colitis a 
correlation between bacteria penetrating the inner mucus layer and 
inflammation was observed by fluorescent in situ hybridization. It has also 
been shown that bacteria penetrate the inner mucus layer before onset of colitis 
in DSS-induced colitis suggesting that bacteria dislocation can be a cause of 
inflammation (discussed further below) 2,64. 
Animal models which develop spontaneous colitis that is potentially linked to 
mucus defects include those with defective ion channel function 64, 
glycosylation alterations 64,67,68,72, innate immune signaling 64 and ER-stress 
and protein processing 56,65,73, all of which are implicated in UC pathogenesis 
23,74–77. This suggests that there are multiple possible causes of mucus defects 
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in UC, but that the result is similar. It also underscores the importance of a 
wide range of factors in maintaining mucus homeostasis. 
Dextran sodium sulphate (DSS)-induced colitis is the most commonly used 
model to study UC 78. DSS is a cytotoxic compound that is thought to act by 
disrupting the intestinal barriers and thereby increase bacterial load at the 
normally sterile tissue and thus drive inflammation. The precise mechanism of 
action is however unclear.  
Petersson et. al. found that the in vivo mucus thickness progressively decreased 
during DSS-treatment, and that the mucus thickness correlated with the disease 
activity index (DAI) 79. The mucus thickness decrease might be an direct effect 
of DSS as it has been found that direct application of 3% DSS on colonic 
explants ex vivo acutely reduced inner mucus layer thickness 2. In addition, it 
has also been found that DSS-treatment increased mucus penetrability to 
bacteria sized beads within 15 minutes after direct application ex vivo, and that 
bacteria could be detected within the inner mucus layer 12 hours after DSS-
treatment in vivo. Similarly, increased bacterial contact with the epithelium 
was observed in Arhgap17-deficient mice, compared to WT controls, after 2 
days of DSS administration which correlated with increased DAI scores 80. 
Exactly how DSS alter the mucus structure is unknown, but dynamic light 
scattering microrheology revealed alterations in the polymer properties of 
intestinal mucus after DSS treatment 81. In both aforementioned cases, 
increased bacterial mucus penetration preceded observable colitis, suggesting 
that a defect mucus barrier and consequent bacteria penetration to the tissue 
might be one of the factors driving inflammation.  
1.1.4.2 Bacterial infection  
The importance of the intestinal mucus in maintaining a symbiotic relationship 
with the gut-residing microbiota is evident from Muc2-/- mice. These mice lack 
a functional mucus layer and bacteria are thus not restricted from the 
epithelium, which leads to development of spontaneous colitis as early as the 
weaning period 3,63,82. The mucus layer is also important for protection against 
pathogenic bacteria as Muc2-/- mice are more severely affected than WT mice 
by infection with Citrobacter rodentium 83. Mice fed a low-fiber diet were also 
shown to be more susceptible to C. rodentium infection 21. In light of the recent 
findings by Schroeder et al, showing that a high-fat/low-fiber diet caused 
structural changes in the mucus barrier which allowed penetration of bacteria-
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sized beads, this increase in susceptibility was probably due to decreased 
mucus barrier function, yet again highlighting the importance of a functional, 
protective mucus barrier 22.  
Although WT mice normally have a functional mucus barrier, they are also 
infected upon C. rodentium challenge, but to a lesser degree than Muc2-/- 
animals. Similar to other pathogens, C. rodentium has evolved means to 
penetrate and circumvent the inner mucus layer, possibly by producing a 
mucinolytic serine protease, and can thus gain access to the epithelium 33,83,84. 
As a response, the host alters its mucus properties in order to clear the infection 
85.  
1.1.4.3 Cystic fibrosis 
Cystic fibrosis (CF) is a severe disease which affects all mucosal tissues in the 
body 86,87. The disease is caused by genetic mutations resulting in a 
malfunctioning Cystic fibrosis transmembrane conductance regulator (CFTR) 
protein, which normally function as a chloride and bicarbonate channel. It was 
long held that defective chloride secretion determined pathogenesis, but recent 
research indicates that the reduced level of bicarbonate  is better correlated with 
the mucus defects observed in CF, as reviewed in Kunzelmann, Schreiber, and 
Hadorn, 2017 87.  
CF patients commonly suffer from both airway and intestinal symptoms. 
Intestinal symptoms includes distal intestinal obstruction syndrome which is 
characterized by obstruction caused by thick, stagnant mucus 88. Gustafsson et 
al. showed that mucus stagnation and attachment to the small intestinal 
epithelium was caused by the lack of bicarbonate, and suggested that this was 
mediated by insufficient unfolding of the MUC2 oligomers after secretion 31. 
Furthermore, increased bacterial load in CF small intestine has been observed, 
suggesting that stagnation of small intestinal mucus can contribute to bacterial 
overgrowth 89. Taken together, CF serves as a clear example of how 
dysregulated mucus dynamics can cause an imbalance at mucosal surfaces that 
results in disease. 
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1.2 The intestinal epithelium  
The very proximal parts of the GI tract, the mouth and esophagus, are lined by 
multiple layers of squamous cells, much like the skin. In contrast, the stomach 
and the intestines are lined by a single layer of epithelial cells that has to 
withstand the strain from ingested foods, bacteria, digestive enzymes and harsh 
acidic environment in the stomach. As discussed above, the mucus layer plays 
a crucial role in maintaining homeostasis, but the epithelium itself has also 
evolved specialized features to withstand the challenges. These include the 
tight junctions between epithelial cells which restrict paracellular passage, the 
presence of a glycocalyx consisting of transmembrane mucins, and 
extraordinarily fast turnover.  
1.2.1 Epithelial cell differentiation 
The turnover time of the intestinal epithelium ranges from 2-7 days 90 as the 
epithelium is continuously renewed by crypt-residing stem cells which can 
give rise to all epithelial cell types 91,92. After initial linage determination, stem 
daughter cells move up the intestinal crypt into the transit-amplifying zone 
where they further divide and differentiate into their respective cell type. As 
the cells migrate up the crypt they continue to differentiate, to finally reach the 
crypt entrance (and villi in the small intestine) as fully differentiated, mature 
cells. Finally, the cells are shed from the tissue and undergo anoikis.  
The epithelium harbors both absorptive enterocytes and several secretory cell 
types including goblet, Paneth, enteroendocrine, and Tuft cells 92. The initial 
determination of absorptive vs secretory cells depend on the Wnt/Notch 
pathways 93. Wnt signaling, via ß-catenin, is crucial for the proliferative 
properties of intestinal crypt cells, but also drives the initial differentiation into 
secretory cells via Atoh1. Notch pathway activation instead drives the 
expression of Hes1, which in turn inhibits Atoh1. By this action, Notch 
signaling inhibits secretory differentiation and instead drives differentiation 
into enterocytes.   
1.2.1.1 Goblet cell differentiation  
Intestinal goblet cells are further differentiated under the influence of several 
transcription factors including Gfi, Klf4, Gata4/6, Foxa1/Foxa2, Klf5 and 
Spdef 93. Spdef acts downstream of Atoh1, Hes1, and Gfi1, and is suggested to 
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be involved in the terminal differentiation of intestinal, as well as airway, 
goblet cells 94–97.  
In the airways, Spdef was shown to reversibly differentiate epithelial club cells 
into goblet cells upon stimulation, with such as IL-13, by driving the 
expression of several genes involved in goblet cell mucus production 96,97. It 
was also found that Spdef did not affect proliferation and thus did not regulate 
the number of secretory cells. Furthermore, Spdef-/- animals were claimed to 
lack submucosal gland goblet cells in naïve conditions and failed to induce 
goblet cell differentiation from club cells when sensitized with OVA. 
However, these latter claims were based on the absence of Alcian blue staining, 
and a recent study showed that although Alcian blue reactivity is reduced in 
Spdef-deficient submucosal glands, PAS reactivity persists and Muc5b is still 
expressed at reduced levels 98. It is thus possible that Spdef increases the 
production of mucins, but that other factors also contribute to the goblet cell 
differentiation. 
Similarly, Gregorieff et. al. found that Spdef-deficient goblet cells in the 
intestine store less material, but are not reduced in number 94. They also 
described morphological alterations of goblet cells in the intestine, including 
the presence of an intact brush border (an epithelial cell feature that is normally 
absent from goblet cells) and decreased theca size. However, this effect was 
not observed in all goblet cells although the authors did not elaborate further 
on this finding. In line with the decreased mucin expression upon Spdef-
deficiency, induced overexpression of Spdef in transgenic mice was claimed 
to increase mucin expression both in vitro and in vivo, further substantiating 
that Spdef is involved in mucin expression and goblet cell maturation 95.  
Induced intestinal overexpression of Spdef was also found to reduce crypt cell 
proliferation 95. Subsequent studies have shown this to be mediated by protein-
protein interaction between Spdef and ß-catenin, which prevent ß-catenin 
induced transcription of cell cycle genes 99,100. However, altered cell 
proliferation has not been found in  Spdef-deficient mice 94,101, or after 
secretory cell-specific overexpression of Spdef in the airways 96. 
1.2.2 Goblet cell subpopulations 
Intestinal goblet cells are generally considered a homogenous cell population, 
differing only in the degree of maturation as they move up the intestinal crypt. 
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However, previous studies have indicated the presence of distinct functional 
subpopulations of goblet cells. Firstly, researchers from Washington 
University showed that goblet cells in the small intestine can form goblet cell 
associated passages (GAPs) which deliver luminal material to dendritic cells 
in the lamina propria 102. These are not present in (proximal) colon from adult 
mice in steady state conditions but can be induced by antibiotic treatment 103. 
As only a subset of the intestinal goblet cells form GAPs, these might comprise 
their own subpopulation.  
Similarly, a small population of goblet cells, referred to as sentinel goblet cells 
(senGCs), at the crypt entrances in the distal colon can endocytose and react to 
microbial associated molecular patterns (MAMPs) when these are present at 
high enough levels 54. The reaction involves compound exocytosis of mucus 
from the endocytotic cell and their neighboring goblet cells. This massive 
secretion is thought to clear the crypt entrance from intruding bacteria, and thus 
protect the epithelium. The senGCs share endocytotic features with GAPs, 
however they are investigated in different tissues (distal colon vs small 
intestine and proximal colon), and differ in their response to cholinergic 
inhibition. Whether these are distinctive or similar subpopulations of goblet 
cells is thus hard to conclude with the present data. 
Secondly, as mentioned in 1.1.3.2, goblet cells along the crypt axis differ in 
their mucus production and secretion rate 32. Goblet cells at the luminal surface 
epithelium have a markedly higher turnover of their secretory cargo, and seem 
almost exclusively responsible for the renewal of the mucus layer in 
unstimulated tissue. Additionally, these cells do not seem to store any mature 
secretory vesicles and does thus not have the typical goblet shape. 
Furthermore, goblet cells do not respond to secretagouges uniformly. As 
mentioned above, apically applied MAMPs only induce secretion from crypt 
entrance cells in mice, as does the tissue irritant mustard oil in rats 54,104. The 
better studied secretory response to acetylcholine is also not uniform along the 
crypt, with higher responsiveness in the lower segments 7,52,54. 
Lastly, several reports have found that intestinal goblet cells have distinct 
glycosylation patterns both in humans and rodents 105–108. For example, up to 
seven distinct populations of goblet cells with different glycosylation profiles 
were found in human colonic crypts. However, the functional relevance of 
these differences is yet to be determined. 
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1.3 Calcium-activated chloride channel regulator 
1 (CLCA1) 
NB: The murine homolog of human CLCA1 was first named Gob-5, then 
Clca3, and has recently been renamed to Clca1. This report uses Clca1.  
Proteomic studies of both human and mouse mucus have revealed abundant 
mucus components besides the gel-forming mucin MUC2, including CLCA1, 
FCGBP, ZG16 and AGR2, of which CLCA1 is one of the most abundant non-
mucin proteins 3,4 (van der Post et al., submitted). CLCA1 belongs to a family 
of CLCAs with four human homologs (CLCA1-4) and eight murine homologs 
(mClca1-2, 3a, b, c, 4a, b, c) 109. Orthologues are also found in other species 
including sheep, pigs and horses and even more distantly related species such 
as Xenopus tropicalis 110. CLCA1/Clca1 are the only homologs that are 
secreted, and the other family members are membrane bound proteins. 
However, parts of these proteins can in some cases be shed from the cell 
surface 111,112.  
1.3.1 Tissue expression 
CLCA1 is primarily expressed by goblet cells in the GI tract, including the 
stomach, small intestine and colon, with the highest expression in the latter 113–
116. This expression pattern follows that of MUC2 along the GI tract and 
CLCA1 is thus suggested to be a core mucus protein 4. In addition, CLCA1 has 
been detected in other mucosal tissues such as uterus, testis, and kidney 113–115. 
CLCA1 expression can also be detected in the airways but mainly in 
correlation with disease, as detailed in 1.3.4.1 117–120.  
1.3.2 Biochemical properties of CLCA1 
The 914 amino acid primary translational product of CLCA1 contain an N-
terminal signal sequence that directs CLCA1 to the ER, from which it is sorted 
to secretory vesicles. Self-cleavage at a conserved site at position 695 or 696 
in CLCA1 and Clca1 respectively results in an approximately 85 kDa N-
terminal product and an approximately 40 kDa C-terminal product 113,116,117,121–
123 (Paper III, Figure 1A). The cleavage takes place intracellularly after which 
both products are secreted, but in vitro studies on constructs with a mutated 
cleavage site have shown that cleavage is not required for secretion 122,123. 
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A catalytic zinc-dependent metalloprotease domain (CAT) in the N-terminal 
part of the protein is responsible for the autocatalytic self-cleavage and the 
cleavage can be abolished by alterations in the conserved HExxE active site 
122–124. The HExxE motif is commonly found in matrix metalloproteases 
(MMPs) and in ‘a disintegrin and metalloproteinase’ (ADAM) proteins which 
are  known to be degraders of extracellular matrix 125. Thus, a role for CLCA1 
in remodeling extracellular mucus is easily conceivable. However, to date the 
only known substrate for CLCA1 is CLCA1 itself, but the physiological 
importance of CLCA1 self-cleavage is largely unknown 122–124. It has been 
suggested that this cleavage might regulate further CLCA1 activity, as CLCA1 
with abolished cleavage was unable to induce calcium-activated chloride 
currents (ICaCC, 1.3.3.1) 122. In contrast, a protease null truncated N-terminal 
CLCA1 protein induced ICaCC, indicating that the proteolytic activity is not 
necessary for ion channel regulation (discussed further in 1.3.3.1 and 4.3.2). 
In addition to the metalloprotease domain, CLCAs also have a cysteine rich 
domain (Cys) and a highly conserved von Willebrand factor type A (VWA) 
domain located in the N-terminal part, as well as a predicted fibronectin type 
III (FnIII) domain in the C-terminus 117,122,124,126. VWAs are normally involved 
in protein-protein interactions (PPI), often in multiprotein complexes. These 
interactions commonly involve divalent cations and the VWA in CLCA1 
contains a conserved metal ion-dependent adhesion site (MIDAS) which seem 
to be important for mediating PPI in CLCA1 126,127.  
The region between the VWA domain and the self-cleavage site, predicted to 
be rich in β-sheets, is highly conserved between the different CLCAs but no 
function has been ascribed to this part of the protein 122.  
1.3.3 Physiological function of CLCA1 
Several functions of CLCA1 has been proposed. In addition to the functions 
discussed in 1.3.3.1-2, it has also been suggested to be involved in both 
immune regulation and cell differentiation 128–132. However, strikingly few 
reports discuss the role of CLCA1 in the secreted intestinal mucus despite the 
fact that this is where it is most abundant. 
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1.3.3.1 Ion channel (regulator) 
When discovered, CLCA1 was predicted to be a calcium-activated chloride 
channel based on early in silico transmembrane domain prediction and altered 
ICaCC  in cells overexpressing CLCA1 in vitro 116. However, several subsequent 
studies have proven that CLCA1 lacks transmembrane domains and that 
CLCA1 expressing cells secrete the protein both in vitro and in vivo, which 
correlates with the abundance of CLCA1 in the intestinal mucus 113,117,121. This 
has led to the conclusion that CLCA1 instead functions as an ion channel 
regulator 117,122,133,134. Recently, it has been suggested that the ion channel 
regulated by CLCA1 is Transmembrane member 16A (TMEM16A), also 
known as Anoctamin-1 127,134.  
1.3.3.2 Mucus properties 
Other reports, mainly based on disease states in the lung (see 1.3.4) suggest 
that CLCA1 is involved in altering mucus properties, secretion and/or 
expression of mucus proteins 113,117–119,123. The location of CLCA1 in the mucin 
granule has led to speculation that it might be involved in the synthesis, 
packing or secretion of mucins 113. These hypotheses have however not been 
tested. 
1.3.4 Implication in disease 
1.3.4.1 CLCA1 in asthma and COPD 
As previously mentioned, CLCA1 has generated interest due to its increased 
expression in the airways in disease states that involve altered mucus properties 
and/or expression of mucus proteins, such as asthma and chronic obstructive 
pulmonary disease (COPD) 118–120,135–137. Asthma is an immunological disease 
that is closely associated with TH2-type cytokines. It has been shown that the 
TH2 cytokines IL-9 and IL-13 can affect the expression of CLCA1, thus 
coupling CLCA1 to the asthma phenotype 135–138. In turn MUC5AC expression 
is thought to be induced by the increased levels of CLCA1 118–120,135,139. 
However, it has not been possible to verify these findings in Clca1-deficient 
mice, which develop asthma and mucin overproduction to the same extent as 
their WT controls 140–142. 
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A recent study found Clca1 to be one of the most upregulated proteins in an 
elastase induced model of COPD 143. The model also induced formation of an 
attached stratified mucus layer in the airways, resembling the colonic inner 
mucus layer. The authors suggest this was a physiological response to 
increased bacteria burden on the airway to limit contact between the epithelium 
and bacteria. It is thus possible that Clca1 is induced to transform the mucus 
organization into a colon mucus-like stratified mucus by yet undefined 
mechanisms, or to release the mucus as a mechanism to limit mucus 
accumulation.  
 1.3.4.2 CLCA1 in cystic fibrosis 
CF is another disease that involves altered mucus properties, both in lung and 
intestine. As previously discussed in 1.1.4.3, it is caused by mutations in the 
CFTR-gene resulting in impaired chloride, and bicarbonate transport in 
epithelial tissues, which results in altered mucus properties. However, residual 
chloride transport by other ion channels can be observed in CF tissues, and can 
ameliorate the disease 144,145. The hunt for the responsible ion channel led to 
the discovery of both CLCA1 and TMEM16A, of which TMEM16A appears 
to be the true CaCC 146–148.  
CLCA1 was identified as a modifier of the gastrointestinal phenotype of CF, 
and a genetic variation of CLCA1 is associated with the development of 
meconium ileus 149,150. Furthermore, both lung and intestinal expression of 
CLCA1 have been shown to be altered in mouse models of CF 151–153, although 
the nature of the alteration seems to depend on genetic background, and thus 
must involve interactions with other factors. As CF mice do not have any lung 
phenotype, a role for Clca1 in the CF lung is not possible to observe in mice. 
However, increased knowledge of CLCA1 function in healthy colon might 
shed light on the involvement of CLCA1 in CF. 
 
As discussed in this introduction, the mucus barrier function has a tremendous 
impact on health, as evident from diseases such as UC, asthma, COPD and CF. 
However, research on mucus has been limited and we thus lack a detailed 
understanding of factors affecting mucus barrier properties. Investigation of 
colonic mucus structure and processing will provide new insight that we hope 
will ultimately lead to the development of new pharmacological therapies. 
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2 AIM 
 
The aim of this thesis was to study colonic mucus in regards of its molecular 
and microscopic structure and processing. This was achieved by testing the 
following hypotheses: 
 Clca1-deficiency results in altered mucus dynamics in regards 
to mucus attachment or mucus growth, and defective mucus 
barrier function (Paper I). 
 
 CLCA1 acts as a metalloprotease in intestinal mucus, and the 
effect of CLCA1 can be blocked by application of 
metalloprotease inhibitors (Paper II). 
 
 MUC2 is a substrate for CLCA1 metalloprotease activity (Paper 
III). 
 
 CLCA1 undergoes molecular processing after secretion into the 
mucus (Paper III).  
 
 Colonic mucus structure can be investigated by ex vivo labelling 
of the mucus using fluorescently labeled lectins (Paper IV).  
 
 Spdef-deficient goblet cells have altered morphology and 
deficient mucus secretory function, which will result in 
defective mucus barrier function (Paper IV). 
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3 METHODOLOGY  
 
3.1 Ex vivo investigation of mucus (Paper I, II, 
IV) 
The ex vivo method of measuring mucus growth, or mucus penetrability to 
bacteria-sized beads, used extensively in this work originated from pioneering 
in vivo mucus characterization in anaesthetized rodents 6. However, the need 
for a method which required less technical skill, and which allows for easy 
pharmacological intervention in e.g. human tissue prompted the development 
of an ex vivo method. The method is discussed in detail in Gustafsson et al. 
2012 7, but in brief the intestinal segment of interest, either dissected from a 
sacrificed animal or obtained by colonoscopy from human patients, is mounted 
in a horizontal Ussing-chamber like system with apical and basolateral 
physiological buffers (Figure 4). The mucus surface is visualized by 
application of either charcoal particles or carboxylated beads that sediment on 
the mucus surface. The mucus thickness can be investigated by measuring the 
distance between the epithelium and the overlaid particles, either under a stereo 
microscope with the aid of a micropipette, or using confocal microscopy.  
 
Figure 4: Schematic diagram of the horizontal Ussing-chamber like system for ex vivo mucus 
characterization. Adapted from 7. 
 
In vivo measurements have shown that the colonic mucus is composed of a 
firmly adherent inner mucus layer and an outer, loosely adherent mucus layer 
3,6, and the ex vivo method replicates these findings 7. The ex vivo chamber 
system has been successfully used to assess changes in mucus properties after 
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in vivo interventions 9,22,64,85,154, and rapid responses to ex vivo pharmacological 
interventions, including ion channel or enzyme inhibitors, or recombinant 
proteins 2,9,13,31,54 and is thus becoming an established method to study intestinal 
mucus properties. 
3.1.1. Measurement of mucus dynamics (Paper I and II) 
Here we have measured mucus thickness over time to investigate mucus 
growth. Measurements at t = 0 minutes give information regarding the adherent 
properties of the mucus layer (i.e. remaining mucus layer thickness after tissue 
flushing), and subsequent growth reveal information concerning mucus 
dynamics. Mucus dynamics includes production, secretion, unfolding of 
secreted mucus, and expansion of the mucus structure as discussed in 1.1.3, 
but it has proven hard to determine the contributing effect of each individual 
factor to baseline growth, as the processes seem to be intricately interwoven. 
For example, as we show in Paper II, application of enzyme inhibitors can 
abolish mucus growth indicating that enzymatically mediated expansion of the 
mucus structure is a main determinant of mucus growth. However, application 
of ion channel inhibitors can similarly block mucus growth (discussed further 
in 3.1.1.1), suggesting that correct ionic milieu is equally important. By 
combining ex vivo mucus measurements with other methods we are now 
gaining a better understanding of the underlying mechanisms that determine 
mucus dynamics at steady state. 
3.1.1.1 Ex vivo application of inhibitors and recombinant enzymes (Paper II) 
A major advantage of the ex vivo system is the possibility to investigate direct 
effects of applied inhibitors and recombinant proteins. In Paper II we used this 
approach to investigate the effect of CLCA1 in colonic mucus. The 
concentration of applied substances was based on published literature when 
available. If no literature was available, or if no effect could be detected at the 
first attempted concentration, the highest concentration without negative 
effects on the tissue was used. In some cases, the solubility of the substance 
determined the concentration that was used.  
In several graphs we present data as Δ growth rate. This was to simplify the 
interpretation of recombinant CLCA1 (rCLCA1)-mediated effects as many of 
the compounds tested in concert with rCLCA1 had an effect on the baseline 
mucus growth. An example is shown in Figure 5; The CaCC/TMEM16A 
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inhibitor CaCCinhA01 essentially abolishes mucus growth in WT colon, thus 
indicating the importance of ion secretion for mucus dynamics. However, 
simultaneous application of rCLCA1 brings the mucus growth rate back to 
slightly higher than normal levels, indicating that the effect of CLCA1 is not 
dependent of TMEM16A in colon. This finding is best represented by the Δ 
growth rate value as presenting only raw growth rate values could give the 
misleading impression that CaCCinhA01 inhibits the effect of rCLCA1.  
 
Figure 5: A) Data of mucus dynamic alterations upon treatment with 
rCLCA1 and an ion channel inhibitor (CaCCinhA01) presented as growth 
rate. B) The effect of rCLCA1 in (A) plotted as Δ growth rate (ΔGR). 
 
Noticeably, many of the tested compounds had an immediate effect on the 
mucus growth rate, which could be observed within 15 min. However, tissue 
ex vivo viability is a limiting factor for studying slow acting compounds, as the 
tissue in general remain stable and viable for only 60 min 7. It is thus possible 
that the lack of effect for some compounds is due to the time window of the 
experiment. 
A further confounding factor when interpreting inhibitor based data is 
specificity. Several inhibitors are claimed to be specific for their target but have 
commonly only been tested in a rather limited in vitro system. For example, 
the ion channel inhibitor niflumic acid (NFA) has been used as a CaCC 
inhibitor is several studies, but has also been shown to block volume-regulated 
ion channels and calcium-dependent potasium channels 155.  
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3.1.2 Mucus penetrability (Paper I, II and IV) 
An important property of the intestinal mucus is its capacity to form a barrier 
against intestinal bacteria 3. To investigate this barrier function ex vivo, 
bacteria-sized beads are applied to the mucus surface and their distribution on 
and in the mucus is investigated by confocal microscopy. This method has been 
used to detect barrier dysfunction in e.g. inflamed epithelium, after dietary 
interventions and in GF mice 22,64,154. In the present work we used this method 
to show that Clca1-/- mice have a functional mucus barrier (Paper I), but that 
Spdef-/- develop a severely dysfunctional mucus barrier phenotype as they age 
(Paper IV). 
Although it has proven useful, several considerations should be kept in mind 
whilst interpreting mucus penetrability. Firstly, mucus penetration by bacteria 
is enhanced by their motility and the ability of certain bacteria to degrade the 
mucus structure 33, whereas the beads penetrate the mucus due to gravity and 
diffusion alone. Thus, a discrepancy between bead penetration and the 
localization of bacteria in the mucus layer can sometimes be observed 9.  
Secondly, mucus penetration is not solely dependent on the pore size of the 
MUC2 oligomeric network, but also on interaction filtering, i.e. interactions 
between the particles and mucus components including lipids and DNA from 
shed cells, thus complicating the interpretation of results 156. In this context it 
should be noted that the beads we use in the presented work are carboxylated, 
which might affect their interaction with the mucus layer. However, in Paper 
IV we confirm data obtained with beads by applying fluorescently labelled 
dextran (FITC-dextran). 
Furthermore, the penetrability assay is typically performed on flushed tissue in 
order to quantify penetrability of the inner mucus layer, which likely gives a 
better representation of the properties of the mucus protective function. 
However, we are at this time uncertain whether the flushing of the tissue itself 
affects mucus properties, although mucus dynamics have been shown to be 
similar before and after removal of the outer mucus layer in vivo 6. 
Combined, the aforementioned factors will in most cases likely result in an 
underestimation of actual mucus penetrability using the carboxylated beads. 
Thus, findings indicating increased bead penetrability suggest that the mucus 
layer is severely affected and most likely will result in increased bacteria 
contact with the epithelium in vivo.  
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A complementary approach for investigating bacteria penetrability is to 
directly stain bacteria in unflushed mucus samples ex vivo 9. This can be 
achieved by applying nucleic acid stain to the mucus and imaging bacterial and 
tissue cells by confocal microscopy. However, presence or absence of a fecal 
pellet in the tissue at the time of sacrifice greatly affect the results and 
mounting unflushed tissue without disturbing the mucus layer is challenging, 
which make this method more useful as a complementary method rather than 
for screening.    
3.1.3 Ex vivo lectin staining of mucus (Paper II and IV) 
One of the major drawbacks with the ex vivo methods discussed above is that 
they rely on application of visible particles to draw conclusion about the 
naturally transparent mucus layer. We thus wanted to develop a technique to 
directly visualize the mucus. Lectins are carbohydrate binding proteins which 
are commonly used for visualization of the mucus in histology 68,107,157. They 
are typically smaller than antibodies, thus more likely to be able to penetrate 
the mucus ex vivo, and fluorophore-conjugated lectins are commercially 
available. Successful application of fluorescently labeled lectins to visualize 
airway mucus bundles led us to develop this technique for intestinal mucus 158.  
The lectins were chosen based on the high abundance of fucose, sialic acid and 
N-actylglucoseamine (GlcNAc) in colonic MUC2 oligosaccharides 24. Both 
UEA1 (α-1,2 linked fucose) and WGA (sialic acid, GlcNAc) gave strong 
reproducible signals from the mucus as discussed in Paper IV. Other lectins 
were tested, including Sambucus Nigra Lectin (SNA, α-2,6 galactose (Gal) 
linked sialic acid), Maackia Amurensis (MAAI and II, Gal (β-1,4) GlcNAc and 
α-2,3 linked sialic acid) and Jacalin and Peanut agglutinin (PNA) which bind 
T-antigen with (Jacalin) or without (PNA) sialic acid. SNA and MAA stained 
structures in the mucus, but these structures were less defined than the staining 
obtained with UEA1 and WGA, and were thus not used further. Both Jacalin 
and PNA gave poor mucus staining ex vivo, likely due to terminal residues 
masking the T-antigen and thus blocking the binding.  
As discussed for different inhibitors (3.1.1.1), the specificity for different 
lectins is less well defined as it is largely influenced by more than the suggested 
simple glycan structures in and ex vivo 159. Thus, we have not investigated the 
exact lectin binding properties or drawn any strict conclusions concerning how 
glycosylation in the different mucus structures differs. Instead, we have only 
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used the lectins as a way to generate informative visualizations of different 
structures in the mucus. However, loss of lectin reactivity should be interpreted 
with caution, as this might be due to differences in glycosylation, or attachment 
of other modifiers rather than lack of the mucus structure per se. In paper IV 
we found that Spdef-deficient mice lacked UEA1 stained intercrypt mucus. As 
these mice also had a strong phenotype in the goblet cells that produced this 
mucus, we are confident in our interpretation that these mice lack the intercrypt 
mucus structure (further discussed in 4.2.2). 
Although not further tested here, we believe that the visualization of the mucus 
will provide useful information regarding how different factors change mucus 
properties. This thus might provide a crucial new tool for future mucus 
research.  
3.1.4 Phenotypic effects of the microbiota (Paper I-IV) 
The profound role of the microbiota in defining important factors in the host 
has become increasingly evident over the past decade. This has also been 
shown for the intestinal mucus layer, where differences in the microbiota 
correlate with different mucus phenotypes observed in mice of genetically 
identical background 160.  
A good example demonstrating how microbiota-mediated mucus phenotypes 
can confound interpretation of data is the case of the inflammasome component 
Nlrp6. It was suggested that Nlrp6-deficieny led to the development of a 
dominant colitogenic microbiota (dysbiosis) which correlated with a defective 
mucus layer, though the causative relationship was not investigated in detail 
161,162. However, the mucus phenotype reported in Nlrp6-/- mice could not be 
reproduced when investigated in our animal facility 54, and dysbiosis was not 
observed in Nlrp6-/- mice when littermate controls were used 163. This indicated 
that neither mucus defects, nor the observed dysbiosis were inherent to the 
Nlrp6-deficiency. The latter study instead showed that maternal and cage 
variables were a stronger determinant of microbiota composition than 
genotype. Thus, differences in microbiota composition can strongly influence 
the mucus phenotype independently of host genotype, and proper animal 
controls are crucial for correct interpretation of data. 
Microbiota composition is dependent on several factors including age, gender, 
mother, and diet 164, which ideally need to be accounted for in experimental 
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design. For this, littermate controls are the gold standard, although cage co-
housing animals of different origin can provide an alternative 164,165. In the 
work presented here, we have used both littermate and cage co-housed mice 
and mice from homozygote breeding programs according to Table 1.  
Table 1: Animal study design for comparison of Clca1-/-and Spdef-/- 
to WT in the different experiments presented in Paper I-IV. 
Paper Experiment Animal set-up* 
Paper I Proteome analysis 1 
 Ex vivo 1 
 IHC and FISH 1 
 DSS 2 
 Microbiota analysis 2 
   
Paper II Effects of rCLCA1 1 
 Clca1-/- phenotypes 1, 3 
   
Paper III All 1 
   
Paper IV Electron microscopy 1 
 Ex vivo 2 
 Biochemical analysis 1 
 Timeline 1, 3 
 PCR and trancriptomics 1 
 DSS 2 
 Colitis 1, 3 
* 1= Separate breeding programs, genotypes separately caged, 2= co-
housed littermates, 3 = phenotypes confirmed in co-housed animals. 
At the time of designing and implementing several of the studies that are 
presented in this thesis, the impact of the microbiota was not fully understood. 
As this understanding has emerged, our group is increasingly using littermate 
controls, either to confirm findings from separately housed mice from 
homozygote breeding programs, or for initial phenotype screening.   
In the case of our Clca1-/- to WT comparison, the littermate controlled 
microbiota analysis in Paper I did not reveal any differences between the 
genotypes. Furthermore, we were not able to detect any mucus phenotype in 
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Clca1-/- mice with the other methods used in this paper. Although an altered 
microbiota can potentially mask a phenotype, we have not repeated 
penetrability, proteomic analysis or immunohistological analysis in samples 
from littermate controls. However, baseline mucus growth, in addition to 
treatment with enzyme inhibitors, has been investigated in co-housed controls 
in order to confirm that the microbiota did not affect this phenotype. Lectin 
staining of the mucus structures were also controlled under co-housed 
conditions. Mass spectrometric analysis of Muc2 absolute quantity and peptide 
abundance in Paper III were performed on samples from separate breeding 
programs which thus might have skewed the data. However, we have 
mechanistic in vitro data that strongly support our in vivo findings, and we thus 
think that our conclusions are valid, although this should be verified in future 
experiments.   
In paper IV we present data from both littermate, co-housed, and separately 
bred and housed mice. As the heterozygote breeding was recently set up we 
are still in the process of acquiring data from littermate controls for all parts of 
the manuscript. So far there has been a very good agreement between the data 
acquired from littermates, co-housed and separately housed mice, thus arguing 
that the effects we describe are true phenotypes caused by the lack of Spdef 
and not by genotype-independent variables.  
 
3.2 Histological examination of fixed tissue 
(Paper I, II, IV) 
Due to the hydrated properties of the mucus, it is poorly preserved in traditional 
fixatives such as formalin. Thus, the common practice in the field is tissue 
fixation in Methacarn (methanol-Carnoy) 166. Furthermore, a fecal pellet is 
required in order to preserve the mucus structure, and no attached mucus can 
usually be observed in tissue sections lacking a pellet. Whether or not this is 
due to poor mucus preservation or actual absence of mucus between pellets is 
under debate 167. However, we consistently detect mucus in interpellet areas ex 
vivo in both flushed and unflushed tissue specimens, and we therefore strongly 
believe that the absence of an attached mucus layer in tissue sections that lack 
a pellet is an artefact.  
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Although it has not been systematically investigated, mucus preservation in 
fixed samples is affected by many factors apart from the choice of fixative, 
such as stool consistency and the actual cutting. Thus, quantifying mucus 
thickness from histological sections generates large variation that is not 
reproduced when mucus thickness is quantified ex vivo (Birchenough, 
unpublished data). 
 
3.3 Proteomics (Paper I, II, III) 
Detailed investigation of sample protein composition, termed proteomics, has 
been made possible by the tremendous development in mass spectrometry. 
This method can provide large scale identification of proteins in a sample, be 
used for protein quantification, investigate post-translational modifications and 
protein interactions 168. Whereas a bottom-up approach is most often used for 
investigation of sample proteome, functional proteomics uses targeted 
methods to study single proteins. The most commonly used proteomic 
approach includes enzymatic digestion of the sample proteins into peptides 
which are separated with liquid chromatography and injected into a mass 
spectrometer. Ionization of the peptides allows determination of the peptide 
mass, and further fragmentation of the peptides yields peptide sequence 
information, after which both are matched against in silico digested proteins 
from sequence databases 169.  
3.3.1 Absolute MUC2 quantification (Paper III)  
Although the intensity of MS1 peaks in a mass spectra roughly correlate with 
the abundance of the peptide, mass spectrometry data is not inherently 
quantitative since the ionization and detection of the peptides depends on their 
chemical properties 169. Instead, absolute quantification is based on spiking 
samples with known amounts of labelled peptides from the protein of interest, 
and comparing peak intensity of the unlabeled native peptide to that of the 
labelled 170. Furthermore, selective reaction monitoring is used to improve the 
sensitivity of the peptide quantification.  
Quantification of MUC2 in tissue has traditionally relied on histological 
examination of Alcian blue-Periodic acid Shiff (AB-PAS) reactivity, MUC2 
immunofluorescent intensity, or PCR-based methods 94,95,171. MUC2 
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concentration in mucus has been less investigated, but has been compared 
between samples by semi-quantitative gel-electrophoresis and blotting 3,39,172. 
However, absolute quantification of MUC2 in mucus has not been performed. 
In Paper III we thus set up a method for this purpose.  
The absolute quantification of Muc2 in mucus generated data with large 
variability. This variability was also observed between technical replicates 
from the same mouse which would be expected to be consistent. We were able 
to reduce variability between technical replicates by introducing 10 µm beads 
for mucus surface visualization, instead of the charcoal particles which were 
initially used (Figure 6A).  However, median mucus Muc2 concentration from 
WT samples still varies considerably between experiments (Figure 6B), but we 
believe that samples prepared and analyzed in parallel can be confidently 
compared, as samples from different groups analyzed at the same time are 
relatively consistent (Figure 6C).  
 
 
Figure 6: A) Standard deviation (St. dev) between technical replicates using either charcoal or 
beads for mucus surface visualization. B) Absolute quantification of Muc2 from WT mucus in 
different experiments (1-4). C) Comparison of Muc2 concentration between WT and a 
knockout mouse strain (KO) at two different occasions (1-2). Data presented as mean ± SEM 
(A) or median (B-C). 
 
Apart from the indication that Clca1-/- animals have slightly higher Muc2 
concentration (Paper III), this method has also been used to compare the effect 
of fiber-free diet on mucus barrier function 22. This study found a correlation 
between mucus barrier defects and reduced Muc2 concentration in mucus, 
further indicating that this method might prove useful in determining 
underlying causes of mucus defects.  
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3.3.2 Cleavage site determination (Paper III) 
Several mass spectrometry based methods have been developed to aid cleavage 
site identification for different proteases, as reviewed by Van den Berg and 
Tholey 173. N-terminal labelling using (N-Succinimidyloxycarbonylmethyl) 
tris(2,4,6-trimethoxyphenyl)phosphoniumbromide (TMPP) enhances ioniza-
tion efficiency and also shifts the retention time of the labelled peptides which 
enhance detection of the labelled peptides. This approach has been used to 
identify the cleavage site of Arg-gingipain B (RgpB) from Porphyromonas 
gingivalis in the MUC2 C-terminus 16. In Paper III we similarly used TMPP-
labelling to identify the CLCA1 cleavage sites in MUC2 N-terminus in vitro. 
Although the identified cleavages were in agreement with in vivo data, they 
should ideally be confirmed using full length MUC2 in vitro or by identifying 
the cleaved peptides in vivo. Proteomes from WT and Clca1-deficient mucus 
were searched using a non-tryptic search algorithm in order to investigate if 
the proposed cleavage peptides could be found in in vivo samples, without 
success. This does however not prove that the peptides are not present, but 
might be due to poor performance of the unlabeled peptides or the higher 
complexity of full proteome samples.  
3.3.3 Mucus proteome analysis (Paper I and II) 
Mass spectrometry can efficiently be used to investigate the full (within the 
limit of detection) proteome of a sample, and can be used as a method to 
compare the relative abundance of large number of proteins 170. However, 
efficient analysis of proteomic data relies on either well defined targets, such 
as known mucus proteins in our case, or well annotated protein databases. 
Unfortunately, the function of most proteins in mucus is unknown, and it is 
thus difficult to perform bioinformatic analyses, or even understand the 
possible physiological implication of variations in single proteins. 
Furthermore, a vast number of the proteins found in the secreted mucus are 
intracellular proteins that likely, but not necessarily, originate from shed cells. 
Although a core mucus proteome of approximately 50 proteins (based on the 
presence of a signal sequence, membrane spanning domain or lipidation) has 
been suggested 174, we cannot exclude that intracellular proteins from shed 
cells have a functional role in the mucus.  
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3.4 Animal models of colitis (Paper I and IV) 
Animal models of colitis has greatly enhanced the understanding of factors 
contributing to IBD, although no single animal model fully recapitulates the 
heterogeneous nature of IBD 175,176. To date approximately 70 models exist 
which can be broadly divided into chemically induced, cell-transfer, congenital 
mutant, and genetically engineered models 177. Of the chemically induced (by 
e.g. DSS, TNBS, acetic acid, and iodoacetamide) colitis models, DSS is one of 
the most frequently used based on its simplicity and reproducibility 78. As 
mentioned in 1.1.4.1, the precise mechanism of DSS action is unknown. 
However, DSS-induced colitis is independent of the adaptive immune system, 
and is thus useful for studying the contribution of the mucus layer and innate 
immunity in colitis.  
3.4.1 Ethical considerations 
In Paper I and IV WT and Clca1- or Spdef-deficient mice were treated with 
DSS in the drinking water in order to investigate altered colitis susceptibility. 
The DSS-experiment on Clca1-/- animals and their controls was performed at 
Freie Universität in Berlin. During DSS-treatment of Spdef-/- and their controls, 
the mice were monitored daily for development of disease by recording weight, 
presence of blood in stool, and overall behavior. In line with our ethical 
permission (74-15), animals were sacrificed upon weight loss >10%, or 
reduced general health indicated by lethargy, kyphosis or inactivity.  
 
3.5 Human biopsy collection (Paper II, III and 
IV) 
Human colon biopsies or material from these are used in Paper II and IV. The 
biopsies were taken from patients with known or suspected colonic disease, 
admitted to the gastroenterological department at the Sahlgrenska hospital. Up 
to 40 biopsies (out of which up to 20, normally 8, were taken for research) 
were collected during colonoscopy of sedated patients under pain relief. 
Sampling of biopsies for research extended the time for colonoscopy 
approximately 5-10 min but sampling was otherwise not believed to cause any 
extra discomfort to the patient, and if it was the examination was discontinued. 
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Patients in the study were given an extra symptom questionnaire to be filled in 
before the colonoscopy. Patient identity was blinded to the researchers.  
Patients were included in compliance with human research ethical committee 
in Gothenburg, Sweden (040-08), and the Declaration of Helsinki. The patients 
received written information about the study in advance and oral information 
and an opportunity to ask questions before being included. Participation in the 
study did not directly benefit the patients. Only adults who were able to give 
consent were included in the research.  
 
3.6 Biochemical investigation of MUC2 (Paper 
III and IV) 
The molecular mass of the unprocessed, non-glycosylated MUC2 polypeptide 
is approximately 500 kDa, which is increased to approximately 2.5 MDa after 
O-glycosylation 17. Thus, conventional biochemical separation techniques such 
as SDS-PAGE is unsuitable for studies of MUC2 178. MUC2 from reduced 
mucus samples can however be separated by SDS-UAgPAGE, a technique 
requiring technical skills and expertise 179. This can be used to investigate 
MUC2 monomers, and also lower order oligomeric states of MUC2, as shown 
in Paper IV. 
To aid biochemical analysis of MUC2, truncated constructs of either N- or C-
terminal MUC2 have been generated 26,27. The molecular masses of these 
truncated proteins are within the working limit of conventional biochemical 
techniques. These constructs have aided the understanding of MUC2 
oligomerization, proteolytic processing of MUC2 by meprin ß, intracellular 
packing of MUC2, and in Paper III we were able show that CLCA1 is able to 
cleave the MUC2 N-terminus by using these constructs 13,26–28,180.  
  
Colonic mucus structure and processing 
32  4 RESULTS AND DISCUSSION 
4 RESULTS AND DISCUSSION 
 
4.1 Colonic mucus structure (Paper IV) 
Functional studies of mucus structure alterations have been performed by 
investigating the penetrability of fluorescent beads into the mucus layer ex vivo 
9,22,64. However, this method investigates the mucus by secondary read outs and 
does not allow for direct visualization of mucus itself. In Paper IV we took 
advantage of the high density of O-glycans present on MUC2 to visualize the 
mucus layer by fluorescently-conjugated lectins ex vivo. By doing so we were 
able to show that, in contrast to previous beliefs, the inner mucus layer has a 
heterogeneous structure. Mucus secreted from the crypts was highly reactive 
to WGA lectin and formed dense plumes which prevented diffusion of particles 
smaller than 0.2 µm, even down to approximately 25 nm. Conversely, mucus 
secreted from luminal surface goblet cells (intercrypt mucus) was highly 
reactive to UEA1 and had different properties in terms of pore size. The 
identification of crypt plumes and intercrypt mucus was primarily based on 
their different reactivity with WGA and UEA1 lectin respectively. However, 
whether the different glycosylation pattern plays a role in determining the 
exclusion properties is currently unknown. 
The presence of dense mucus plugs over the crypt openings make sense in 
terms of preventing bacteria reaching the stem cells, as disruption of the stem 
cell niche would have detrimental effects. It is also possible that the presence 
of only crypt covering plumes would result in a stagnant mucus layer and that 
the intercrypt mucus has developed to flush and lubricate the surface.  
The discovery of two distinct mucus types in the colonic tissue is similar to 
what has also been observed in pig airways where MUC5B from submucosal 
glands forms bundles that rolls over the tissue and becomes coated in 
MUC5AC from goblet cells at the epithelial surface 158. MUC5B and 
MUC5AC are not only expressed at distinct places but also have different 
glycosylation, as observed by their different lectin reactivity. Although the 
system in the airway relies on two different, but very similar mucins, there 
appears to be many homologies between the airways and the intestine. 
Elisabeth Nyström 
4 RESULTS AND DISCUSSION  33 
However, the rationale for having mucus structures with different properties in 
the intestine needs to be further investigated. 
The homogenous appearance of the mucus layer in fixed tissue does contradict 
our finding of a heterogeneous mucus structure ex vivo 3,8. One reason for this 
discrepancy might be compression of the mucus gel in histological sections, as 
these have to contain a fecal pellet in order to preserve the mucus layer. The 
presence of a pellet might compress the plumes to the level of the epithelial 
surface, and/or induce increased formation of the intermixed UEA1/WGA 
material seen as a fine network at the mucus surface in our ex vivo experiments, 
which we believe corresponds to the stratified mucus observed in fixed 
sections. However, we have so far not found an ex vivo method to study the 
mucus structure under altered luminal pressure. It is also possible that the 
handling of the tissue for ex vivo investigation in of itself induces artefacts, 
(e.g. increased secretion from the crypt goblet cells) that result in increased 
plume volume. However, as the architecture with crypt plumes and intercrypt 
mucus can be observed in unflushed tissue which has been subjected to 
minimal handling we believe that what we have described here represents the 
physiological state 
 
4.2 Intercrypt goblet cells (Paper IV) 
4.2.1 Identification of intercrypt goblet cells (Paper IV) 
The UEA1-reactive intercrypt mucus was secreted from goblet cells at the 
luminal epithelial surface. Based on four lines of evidence, we suggest that 
these cells, here called intercrypt goblet cells (icGCs), represent a novel 
subtype of goblet cell. Firstly, icCGs are morphologically distinct and do not 
have the typical goblet shape due to reduced theca size since they do not store 
their secretory cargo 32. They are thus mostly overlooked in investigations of 
goblet cells, especially with AB-PAS staining. They can however be easily 
identified by staining for apo-MUC2, due to their high rate of MUC2 synthesis 
(discussed further below).  
Secondly, icGCs seem to have a different glycosylation machinery since they 
produce predominantly UEA1 reactive (presumably fucosylated) material, and 
very little WGA reactive material. Whether this is due to a transcriptional shift 
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in the glycosylation machinery as part of GC terminal differentiation is yet to 
be determined. Furthermore, we have not examined how the different 
glycosylation relates to mucus properties. 
Thirdly, mucus secreted from icGCs has different penetrability properties 
compared to the crypt covering plumes, and is more penetrable to 0.2 µm 
beads. This seem to represent a weak point of the mucus structure as we have 
noted that bacteria almost exclusively penetrate intercrypt mucus in mice that 
have increased bacterial penetration (Figure 7, unpublished). In steady state 
condition, however, bacterial access to the intercrypt mucus is limited by the 
dense intermixed UEA1/WGA network.   
Fourthly, these cells have a higher Muc2 production and secretion rate 
compared to other goblet cells which might provide a flushing effect that can 
prevent the tissue from infection under normal conditions 32.  
 
 
Figure 7: x/y, and x/z-projections of colonic explant ex vivo. Bacteria can be detected in 
intercrypt mucus in unflushed colonic mucus of a mouse model with increased mucus 
penetrability. Mucus was stained with WGA (grey) and UEA (red). Bacteria and host cells are 
stained with Syto9 (green). Yellow dashed lines outline examples of crypt plumes.  
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4.2.2 Loss of intercrypt goblet cell function in Spdef -/- mice 
results in a dysfunctional mucus barrier (Paper IV)  
Spdef-deficient mice were found to have a loss-of-function phenotype in 
icGCs. In line with a previous report, the icGC phenotype included an 
increased number of microvilli on the apical surface, ER-enlargement and 
reduced theca size compared to WT icGCs 94. We further found that these 
alterations correlated with a secretory defect. Thus, although we did identify a 
difference in the transcription of some glycosylation pathway proteins in Spdef-
/- goblet cells, we think that the lack of UEA1-intense intercrypt mucus was 
due to an actual loss of this mucus, rather than altered glycosylation. Lack of 
functional icGCs strongly correlated with a defective mucus barrier, with 
decreased mucus thickness and an increased penetrability to beads, indicating 
the importance of the intercrypt mucus for the formation of a functional mucus 
barrier.  
As the abnormal mucus phenotype in Spdef-deficient mice developed with age, 
we do not believe that Spdef is directly regulating icGCs, but that the effects 
observed in those cells are secondary to the loss of Spdef. Furthermore, our 
transcriptional data from 6-week-old Spdef-/- and WT animals did not reveal 
any difference in the transcription of core mucus genes such as Muc2 and Agr2, 
although these genes were altered in 11-week-old mice. This suggests that 
Spdef, despite earlier reports, is not directly regulating Muc2 expression 
94,95,181. Unfortunately, due to poor knowledge of many of the goblet cell and 
mucus-specific proteins, gene ontology annotation enrichment analysis of 
altered gene expression in the goblet cell fraction did not reveal any specific 
pathways that are regulated by Spdef, apart from O-glycan processing.  
Mucus quality defects have been noted in UC but it has remained unknown 
whether these defects are a result of or a driving factor in inflammation. As 
Spdef-deficient mice have a slow progression of colitis (compared to 
chemically induced colitis models) we were hoping to resolve this issue. 
Indeed, a strong mucus phenotype developed before overt signs of 
inflammation, such as crypt elongation or immune cell infiltration 182. 
However, the number of CD45+ cells in the tissue increased before we noted a 
drastic change in mucus penetrability. It is thus possible that subtle mucus 
changes occur at earlier time points, which increase bacterial contact with the 
tissue and drives immune activity. Since we can see both mucus and immune 
changes before the onset of colitis, we were unable to resolve the 
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aforementioned question. This shows how interconnected the mucus, 
epithelium and immune system are in maintaining homeostasis. We do 
however believe that a more detailed investigation of the temporal aspects of 
the phenotypes observed in Spdef-deficient mice will help to shed light on the 
relation between mucus defects and colitis development.  
 
4.3 Effects of CLCA1 in mucus (Paper I and II) 
4.3.1 Mucus phenotype in Clca1-deficient mice (Paper I and 
II) 
Due to the abundance of CLCA1 in colonic mucus we first hypothesized that 
it has a structural role in the mucus and that loss of CLCA1 would weaken 
mucus barrier function. Alternatively, we hypothesized that the proposed 
protease effect of CLC1 would have profound effect on the mucus structure, 
that would affect mucus dynamics. Thus we investigated mucus barrier 
function and dynamics in Clca1-deficient mice. However, no altered mucus 
phenotype could be found in Clca1-deficient mice by using IHC to study the 
mucus layer stratification or goblet cell appearance. Furthermore, Clca1-/- mice 
did not have a defective mucus barrier as they had an impenetrable mucus layer 
ex vivo and had a good separation between the tissue and bacteria as shown by 
FISH of intestinal sections. Additionally, WT and Clca1-deficient mice had 
similar mucus dynamics in naïve and CCh stimulated tissue.  
A previous study investigating Clca1-/- airways suggested that their lack of 
abnormal phenotype was due to increased expression of Clca2 (previously 
mClca5) 142. This led us to think that the lack of an intestinal mucus phenotype 
in Clca1-/- animals could similarly be due to increased expression of other Clca 
homologs in the intestine. However, we could not find elevated protein levels 
of any other Clca-family member in the mucus by proteomics.  
Conversely, as we investigated CLCA1 function using protease inhibitors 
(discussed further in 4.3.2), we found a striking difference between WT and 
Clca1-/- mice. Whereas WT baseline mucus growth was inhibited by the 
metalloprotease inhibitor EDTA, similar to what we found in GF mice and 
human ex vivo explants, the Clca1-/- mucus growth rate was not significantly 
altered. Instead, mucus growth in Clca1-/-  explants was completely inhibited 
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by cysteine-protease inhibitors, whereas these only had minor effects in WT 
tissue. It thus appears that lack of Clca1 induces cysteine protease activity, 
although the responsible protease and the regulatory mechanisms so far remain 
unknown.  
Despite the masking of growth phenotype in Clca1-/- by a cysteine protease, 
there are differences in the processing of the mucus between WT and Clca1-/- 
mice, evident by lectin staining of the mucus. Alterations in the mucus 
structure were primarily observed at the mucus surface, whereas the tissue 
proximate mucus appeared normal (not shown). The surface structure of 
flushed intestinal mucus in WT animals is, as we also describe in Paper IV (see 
4.1), relatively smooth, whereas it was more condensed in Clca1-/-. This effect 
was even more pronounced when unflushed mucus was investigated (Figure 
8). We thus suggest that CLCA1 is involved in the transition from inner to 
outer mucus. The mechanism for this is further discussed in 4.4. 
 
Figure 8: Representative x/y-projections of the mucus surface from unflushed WT and Clca1-/-
explants stained with WGA (grey) and UEA (red). 
4.3.2 Effects of recombinant CLCA1 in mucus (Paper II) 
To further characterize the function of CLCA1 in mucus we investigated the 
effect of exogenously applied rCLCA1 ex vivo. Ex vivo mucus application of 
recombinant proteins has previously been successful in both rescuing mucus 
phenotypes, and providing functional evidence for proteins 9,13. Application of 
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rCLCA1 resulted in a marked increase of the mucus growth rate, as well as 
increased penetrability of the mucus. Importantly, the innermost mucus 
remained impenetrable, suggesting that CLCA1 enhance the conversion 
between the inner and outer mucus layer. rCLCA1 application also slowed the 
movement of beads above the mucus surface which we interpreted as increased 
viscosity at the mucus/liquid border due to excess processing of the mucus 
structure.  
The effect on the mucus of rCLCA1 was shown to be mediated by the 
metalloprotease activity in the N-terminus of CLCA1, as the effect could be 
blocked by the metalloprotease inhibitor EDTA but not the cysteine- and serine 
protease inhibitor cOmplete protease inhibitor (EDTA-free), and was 
abolished by a protease null CLCA1 mutation. Similar inhibition as with 
EDTA was found with EGTA and TPEN, which preferably chelate calcium 
and zinc respectively. Although the protein sequence suggest binding of both 
calcium and zinc, the requirement for different ions needs further testing. We 
did not note any inhibition by Batimastat, a commercial MMP inhibitor 
previously reported to have inhibitory effect on CLCA1 in vitro 122. Another 
study also failed to detect inhibition of CLCA1 with Marimastat, an inhibitor 
similar to Batimastat 123. Although CLCA1 has similarities with MMPs and 
ADAMS, it lacks several of their common features and we therefore suggest 
that CLCA1 constitutes a novel class of proteases. 
Importantly, the CLCA1-induced mucus growth increase was not mediated by 
ion secretion. CLCA1 has repeatedly been reported to act as an ion channel 
regulator of CaCCs, potentially by stabilizing TMEM16A at the cell membrane 
117,122,127,133,134. The interaction between CLCA1 and TMEM16A is suggested 
to be mediated by the VWA domain in CLCA1, and the VWA domain alone 
was sufficient to induce ICaCC in vitro 127. However, the specificity of the 
interaction, i.e. whether or not other proteins containing a VWA, or isolated 
VWA domains from other proteins, could elicit the same response was not 
tested. The investigators further claimed that CLCA1 stabilized TMEM16A at 
the apical membrane by inhibiting internalization of TMEM16A, evident by 
membrane localization of both CLCA1 and TMEM16A when co-expressed. 
However, the investigators did not investigate the co-localization in detail, and 
although CLCA1 has also previously has been suggested to be membrane 
associated in vitro, we have not observed any membrane staining of CLCA1 
in intestinal sections 116,117,133,134. Regarding CLCA1-induced mucus growth, if 
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TMEM16A modulation was involved in this process then it should be blocked 
by the potent TMEM16A inhibitor CaCCinhA01 155,183. Although less specific, 
DIDS and NFA has also previously been shown to inhibit CLCA1- mediated 
ion currents in vitro 116,133. However, none of these inhibitors prevented the 
CLCA1-mediated growth rate increase, thus suggesting that the proposed ion 
channel regulatory effect of CLCA1 does not play a role under these 
circumstances. 
Research concerning the ion channel regulatory properties of CLCA1 has 
primarily focused on airway tissue, and it is possible that CLCA1 expressed in 
the airways in asthma and COPD has another function than constitutively 
expressed intestinal CLCA1. However, investigation of airways from Clca1-/- 
mice did not reveal alterations of calcium-activated chloride currents in either 
naïve or IL-13 treated conditions 141, and Clca1-/- mice did not respond 
differently to WT mice in a virus induced airway model of hyperplasia 142.  
The involvement of CLCA1 in the inner to outer mucus layer conversion might 
be a key determinant for smooth distal transport of mucus and thus prevent 
stagnation. This could pose an explanation of the result from a previous report 
showing that restoration of reduced Clca1 expression ameliorated CF mucus 
obstruction in small intestine 152. This was not due to altered electrostatic ion 
transport, however other possible mechanisms were not investigated.  
Furthermore, this possibly sheds new light on the role of CLCA1 in diseases 
which have mucus stagnation as a hallmark pathological feature. As discussed 
in 1.3.4.1, there has long been a belief that the overexpression of CLCA1 noted 
in TH2-type asthma and COPD is the cause of the goblet cell hyperplasia and 
mucin overproduction typical for these diseases (reviewed in Patel et. al., 2009 
110). It is however possible that the overexpression of CLCA1 is a response 
induced to facilitate removal of increased mucus, and also that there are 
unknown feed-back loops that make it challenging to dissect whether CLCA1 
expression drives mucin expression or vice versa. This could also account for 
the contradictions in the literature regarding this matter 119,135,137,140,141. The 
recent finding that airway mucus becomes more similar to colonic mucus in a 
model of COPD further argues that the role of CLCA1 in diseased airway is 
similar to its normal function in the intestine, which we suggest is to facilitate 
removal of mucus 143. We therefore propose that the role of CLCA1 in these 
diseases should be reconsidered and that CLCA1 may be considered a friend 
rather than a foe. 
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4.4 MUC2 cleavage by CLCA1 (Paper III) 
Our data in Paper III strongly suggest that CLCA1 cleaves MUC2. This was 
shown using both an in vitro assay and by identifying differences in the Muc2 
peptide distribution in Clca1-/- mice compared to WT. 
Recombinantly expressed and purified CLCA1 and MUC2-terminal proteins 
were used in an in vitro assay which showed that CLCA1 was able to degrade 
the MUC2-N, but not -C, terminus. However, the purification fraction 
containing the highest amount of 85 kDa N-terminal rCLCA1 was only partly 
able to process the MUC2 construct, whereas a fraction containing a smaller 
N-terminal fragment harboring the CAT/Cys+VWA domains of CLCA1 
completely degraded MUC2 into 4 cleavage products. Thus we believe that the 
CAT/Cys+ VWA secondary N-terminal product of CLCA1 is more 
enzymatically active (further discussed in 4.5.1). We do not fully understand 
how this product is generated in our in vitro system, but speculate that it is due 
to low-grade spontaneous degradation of the full length N-terminus, or 
alternatively due to the presence of an activating protease in the in vitro 
expression system. Preferably, we would aim to express the CAT/Cys+VWA 
domains as a truncated protein in order to further characterize it; however, our 
attempts thus far have been unsuccessful, as this protein seems to be retained 
in the ER of the expressing cells. Whether or not this is an inherent problem or 
can be resolved by using another cell line is a subject for future investigation.   
Analysis of the CLCA1-mediated MUC2 cleavage products revealed three 
possible cleavage sites in MUC2-N; IRL754-755IGQ, TAL774-775ATS and 
VIQ940-941RDE, in the E2-TIL´interface, TIL´-domain, and VWD3 domain 
respectively. The compact organization of the D-assembly subdomains argues 
that IRL754-755IGQ  is the actual CLCA1 cleavage site as this site is more 
exposed 14. This would indicate that CLCA1 is able to cleave off the D1-D2 
assemblies from MUC2.   
Altered Muc2 processing as determined by peptide abundance was found in 
Clca1-/- intestinal mucus compared to WT. Although absolute quantification of 
total Muc2 only trended towards being increased in the knock-out animals, the 
absolute amounts of the peptide located in the D1 assembly was significantly 
higher in Clca1-deficient mice. However, the ratio of the D1 peptide to the 
reference peptide is still less than one in these mice, which indicates that D1 is 
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additionally processed. Furthermore, comparison of the relative abundance of 
Muc2 peptides in mucus from WT and Clca1-/- again revealed differences in 
the D1 assembly region, where Clca1-deficient mice have comparatively 
higher abundance of peptides.  
The effect on the mucus structure by the cleavage of the D1-D2 assemblies 
proposed herein is still not understood, although it seems to have a large impact 
on the transition from inner to outer mucus layer as Clca1-/- animals have a 
markedly different outer mucus layer organization (see 4.3.1). Based on the 
similarity between MUC2 and VWF, we suggest that D1-D2 stabilize the 
oligomeric bundles of MUC2 which are formed intracellularly 28, and that 
CLCA1 either actively aids the unfolding of MUC2 or stabilizes the unfolded 
state by removing or altering D1-D2 conformation. Although the unfolding of 
MUC2 has previously been assumed to be spontaneous upon increased pH and 
reduced concentration of calcium, our results suggest that other factors such as 
CLCA1 might be crucial for the process.  
 
4.5 Biochemical properties of CLCA1 (Paper II 
and III) 
4.5.1 Regulation of CLCA1 activity (Paper II and III) 
As shown and discussed in both Paper II and III, CLCA1 is very abundant in 
colonic mucus. Thus, its enzymatic activity is probably very tightly controlled. 
Enzymatic activity can be regulated by a broad range of factors including pH, 
endogenous inhibitors, presence of a pro-peptide and allosteric hindrance. As 
CLCA1 is similar to MMPs and ADAMS which are expressed as zymogens, it 
has been suggested that removal of a pro-peptide is involved in CLCA1 
activation. However, Yurtsever et al. claimed this not to be the case as they 
could not detect loss of an N-terminal tag after in vitro expression of CLCA1 
122. However, in our opinion the design of the experiment cannot exclude the 
existence of a pro-peptide, and this thus need further testing.  
In the same paper, it was also shown that autocatalytic cleavage is required for 
the ability of CLCA1 to act as an ion channel regulator, and this was thus 
suggested as a regulatory mechanism. However, we could only detect cleaved 
CLCA1 in intestinal mucus samples, which contradicts the hypothesis of self-
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cleavage as a fine-tuning regulation. Furthermore, a CLCA1 mutant with 
abrogated cleavage was able to induce mucus growth to the same extent as WT 
CLCA1, adding to the evidence that self-cleavage is not required for CLCA1 
activity in the intestine. 
We were able to detect a previously uncharacterized N-terminal product of 
CLCA1 in fresh intestinal mucus samples by Western blot. Based on the 
molecular mass and identification with antibodies against different epitopes in 
CLCA1, we suggest that this product contain the catalytic CAT/Cys domain 
together with the VWA domain. The in vitro MUC2 cleavage assay (discussed 
in 4.4) further suggests that this product is more enzymatically active, and we 
thus propose that a second cleavage of the CLCA1 N-terminus regulates 
enzyme activity. This cleavage would be between the VWA and the β-sheet 
rich (BSR) domain, but the exact cleavage site and the responsible enzyme for 
the cleavage remain unknown. Furthermore, although the CAT/Cys+VWA 
product was resistant to limited proteolysis with trypsin, it appears to be more 
unstable than the full N-terminus as it was lost upon freezing and thawing of 
samples. Thus, the activity after activation might be limited by a decreased 
half-life. However, this concept needs further investigation. 
4.5.2 CLCA1 interactions and domain structure (Paper III) 
In Paper III we show evidence that CLCA1 forms large oligomers consisting 
of both N- and C-terminal CLCA1. These oligomers are held together by non-
covalent association between the N- and C-termini, and by C-terminal 
dimerization via disulfide bonds. The non-covalent interaction between the N- 
and the C-termini is possibly mediated by interaction between the VWA and 
FnIII domain, although this was not investigated. Oligomerization often serves 
to stabilize a protein structure, but might also confer regulatory functions if it 
is dependent on environmental factors such as pH. Thus, further investigation 
of CLCA1 oligomerization might provide useful input regarding CLCA1 
function and regulation.  
Clca1 was also identified in bands corresponding to different Muc2 oligomeric 
states in SDS-AgPAGE analysis of colonic mucus, indicating an interaction 
between Clca1 and Muc2. As we discuss in Paper III, it can be envisioned that 
Clca1 has to bind its target, Muc2, in order to maintain proximity to its 
substrate after secretion. However, other functions of this interaction are 
possible and Clca1 might have yet undiscovered structural roles in the mucus.  
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Limited proteolysis of CLCA1 indicated that the CAT/Cys, VWA and FnIII 
form structural domains that are protected against proteolysis. Furthermore, 
the combined CAT/Cys+VWA domains also seems largely resistant to 
proteolysis, indicating that together these form a functional truncated product. 
Unfortunately, we do not have any antibody directed against the BSR domain 
and could thus not investigate this region in further detail.  
Secretion of a truncated CLCA1 protein encompassing the full N-terminus 
failed due to ER retention. Two shorter truncated N-terminal proteins (1-300/ 
1-477) were also poorly secreted although ER retention was not proven in these 
cases. This indicates that the full CLCA1, including the C-terminal part, is 
needed for correct protein folding and processing. However, we cannot 
exclude that the ER-retention is cell line specific, and therefore this needs 
further investigation. 
 
4.6 Human mucus (Paper II, III and IV) 
The objective for our studies is to better understand the physiology of the 
human intestinal mucus and epithelium. Thus, investigation of human samples 
has been crucial to confirm that our results using mice as a model organism are 
translational. By collaboration with the gastroenterology unit at the 
Sahlgrenska University hospital we have been fortunate to obtain fresh 
intestinal biopsies from colonoscopy examinations. We have thus been able to 
investigate human mucus structure and properties ex vivo by lectin staining, 
bead penetrability, mucus growth rate dynamics in response to CLCA1 and 
protease inhibitors, and have also collected mucus samples for biochemical 
investigation of CLCA1. 
Lectin staining of human sigmoid colon revealed a similar pattern to that 
observed in mice, with crypt-covering plumes surrounded by intercrypt mucus 
that merged at the mucus surface (Paper IV). However, the lectin reactivity 
was different in human samples compared to mice. Whereas GlcNAc and sialic 
acid-binding WGA primarily stained crypt mucus in mice, it seemed to 
preferentially bind intercrypt mucus in human samples. LEL, which like WGA 
binds different GlcNAc containing structures, gave a similar but not identical 
staining pattern. In contrast, fucose-recognizing LTL gave stronger staining of 
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the crypt plumes in humans. LTL has so far not been tested in mouse tissue, 
but UEA1 which recognizes α1-2-linked fucose gives strong staining of 
intercrypt mucus in mouse. Investigation of the glycosylation patterns is of 
interest, especially in relation to its changes during inflammation 184. However, 
here we have not aimed to investigate glycosylation per se but merely use it as 
a tool to visualize the intestinal mucus. That said, future studies of how the 
glycosylation and concurrent lectin reactivity, as well as the overall mucus 
structure, change during inflammation are both feasible and highly interesting.  
Human intercrypt mucus was penetrable to 0.2, but not 1 µm carboxylated 
beads similar to what was found in mouse mucus. Mucus from healthy human 
subjects has previously been shown to be impenetrable to 0.5 – 2 µm beads 64. 
It thus seems as there is a size exclusion limit in the intercrypt mucus between 
0.2-0.5 µm.  
As we show in Paper II and in agreement with previous findings 7, human 
baseline mucus growth rate is in a similar range to that of mouse mucus. 
Furthermore, human mucus growth was inhibited by addition of EDTA, and 
was increased by rCLCA1 treatment. These results correlate with those from 
mouse samples, suggesting that metalloproteases are involved in the mucus 
dynamics in both species and that CLCA1 is a likely candidate for this effect.  
Investigation of CLCA1 from collected human mucus and epithelium by 
Western blot identified similar biochemical processing of CLCA1 in human as 
to mouse (Paper III). We thus only identified fully cleaved N- and C-terminal 
CLCA1 in human mucus samples, which were found in large oligomers when 
investigated under native conditions. Similar to murine Clca1, human C-
terminal CLCA1 dimerization was also observed. Importantly, we were able 
to detect the truncated second N-terminal product we have suggested is the 
fully active CLCA1 in fresh human mucus, implying that this processing event 
is conserved in both species. 
Lastly, the in vitro MUC2 cleavage assay used both CLCA1 and MUC2-
terminal proteins that are based on the human sequences. Thus, any effect 
observed here should recapitulate human conditions. However, we were able 
to find evidence for the same Muc2 cleavage event in mucus from mice, again 
suggesting good translatability between human and mouse CLCA1 function. 
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By using an ex vivo set up to measure colonic mucus properties such as mucus 
growth in native conditions or in response to exogenous application of proteins 
or inhibitors, penetrability to bacteria sized beads, and investigation of lectin 
reactivity of the mucus, in combination with mass spectrometry and 
biochemical methods we were able to conclude that: 
• Deficiency of Clca1 in colonic mucus does not result in altered mucus 
dynamics ex vivo due to compensatory activity by a cysteine protease. 
Neither does Clca1-loss results in a defective mucus barrier in terms of 
mucus penetrability, but alters the outer mucus layer structure.  
• CLCA1 acts as a metalloprotease in intestinal mucus. 
• MUC2 is a substrate for CLCA1 metalloprotease activity, which cleaves 
off the D1-D2 assemblies of MUC2. This transformation is important for 
the transition from inner to outer mucus layer. 
• CLCA1 forms oligomeric assemblies in mucus, mediated by C-terminal 
disulfide-bonds and non-covalent interaction between CLCA1 N- and C-
termini. 
• A novel N-terminal product of CLCA1, consisting of the CAT/Cys and 
VWA domains, is detected in mucus and is more proteolytically active than 
the full length N-terminal CLCA1.   
• Microscopic mucus structures can be visualized and investigated by 
application of fluorescently labelled lectins ex vivo. 
• The inner mucus layer is not a homogenous structure, but consists of dense 
mucus plumes covering the crypt openings, interconnected by intercrypt 
mucus that has a less dense structure. Crypt plumes and intercrypt mucus 
merge to form dense nets.  The organization of different mucus structures 
can be visually distinguished ex vivo due to their different lectin reactivity.   
• Intercrypt goblet cells are a functional subtype of goblet cell. Loss of 
intercrypt goblet cell function in Spdef-/- results in a defective mucus barrier 
and subsequent development of colitis.  
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Our observations describing mucus structure and processing have shed new 
light on determinants of intestinal mucus barrier function. However, this field 
is far from fully explored. We hope that the development of an ex vivo mucus 
visualization method using fluorescent lectins will provide more detailed 
information of how mucus is structured, not only in colon, but also in the small 
intestine and proximal colon. Furthermore, investigation of mucus structural 
alterations in disease, and different mouse genetic models, is likely to give 
useful information of how barrier defects arise and how it relates to disease 
development. 
Our identification of icGCs as a functional subpopulation of goblet cells, 
together with the previous identification of senGCs, strongly indicates that the 
goblet cells are less homogenous as a cell type than previously thought. 
Development of single cell transcriptomics can be envisioned to further define 
and characterize different goblet cell subpopulations, which might provide new 
insight into goblet cell functions apart from mucus secretion. 
Our finding that CLCA1 is able to process MUC2 in order to loosen the mucus 
structure presents a novel function for CLCA1. However, further 
characterization of the interaction between CLCA1 and MUC2, as well as of 
the regulation of CLCA1 activity is needed to fully understand the function of 
CLCA1 in vivo.  
Increasing our understanding of the mucus processing activities of CLCA1 will 
further decipher the involvement of CLCA1 in diseases such as asthma and 
COPD. The long held belief has been that CLCA1 is responsible for the mucus 
hypersecretion and plugging in these diseases. However, our results suggest 
that CLCA1 is rather increased in order to facilitate removal of the mucus. A 
recent study observed that airway mucus is stratified and anchored to the 
epithelium in COPD and CF, thus resembling colonic mucus 143. As Clca1 was 
found to be one of the most upregulated proteins in the mouse-model employed 
by this study, it can be speculated that Clca1 is part of the transition to a colon-
like mucus phenotype, possibly by stabilizing the stratified organization. This 
hypothesis requires further studies in suitable models. In addition, 
investigation of CLCA1 in lung disease, e.g. if it is found in the more 
proteolytically active form or not, and whether or not CLCA1 can process the 
airway mucins MUC5AC and MUC5B should help to clarify the role of Clca1 
in pulmonary diseases.  
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